Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.20.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Cash equivalents    
Research and development costs 96,943 $ 206,943  
Incometax likely hood percentage, description     A valuation allowance is applied when in management's view it is more likely than not (50%) that such deferred tax will not be utilized.    
Revenues others $ 16,200 $ 16,200  
Common Stock Options [Member]          
Antidilutive securities excluded from computation of net loss per share, amount     468,619 340,619  
Common Stock Warrants [Member]          
Antidilutive securities excluded from computation of net loss per share, amount     46,154 213,494  
Conversion of Debentures [Member]          
Antidilutive securities excluded from computation of net loss per share, amount     66,000 66,000  
Conversion of Debentures [Member] | Shares May Be Converted into Bridge Notes [Member]          
Conversion of shares     8,079,617 1,823,631  
Conversion price per share $ 0.22 $ 2.05 $ 0.22 $ 2.05  
Conversion of Redeemable Convertible Preferred Stock [Member]          
Antidilutive securities excluded from computation of net loss per share, amount     309,988 240,000